source
- Novo Nordisk licenses weekly oral obesity peptide from Hengrui in up to $2.6 billion dealNovo Nordisk has signed a licensing agreement with China's Hengrui Pharma for a once‑weekly oral peptide, HRS‑1596, aimed at obesity and other metabolic conditions. Novo will pay $300 million upfr…
- Midterm elections could reshape drug pricing, Medicaid funding and research support, industry leaders warnThe November midterm elections are set to influence major health-care policy debates in Washington, according to STAT+. Industry leaders say the outcome could affect Medicaid funding levels, the p…